Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206993 | 0.88 | RAB9A (0.66) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL17014792 | 0.84 | CYP19A1 (0.70) | ALDH1A1KDM4ERAB9ANPC1CYP3A4 | |
| SCHEMBL6225037 | 0.83 | EIF4E (0.46) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL1821128 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL11461511 | 0.82 | SREBF2 (0.65) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL2781370 | 0.81 | KDM4E (0.85) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL23742623 | 0.80 | RAB9A (0.63) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL11146948 | 0.80 | RAB9A (0.55) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL11213828 | 0.79 | SREBF2 (0.82) | ALDH1A1SREBF2KDM4EKMT2AAR | |
| SCHEMBL11212983 | 0.79 | SREBF2 (0.82) | ALDH1A1SREBF2KDM4EKMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2215066-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| US-4197306-A | CONTROL OF INSECTS AND ACARIDS | UNIROYAL, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153703-A | Method of controlling insects and acarids with certain aryl-substituted thiazoles | UNIROYAL, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 871/4885SREBF2 223/4885KDM4E 1780/4885 |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | ALDH1A1 2606/4885SREBF2 4408/4885KDM4E 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.